| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Tamarixetin targets multiple pathways including oxidative stress-responsive pathways and inflammatory signaling. It exhibits potent antioxidant activity through free radical scavenging and metal chelation. The compound inhibits pro-inflammatory cytokine production and modulates NF-κB signaling. It also demonstrates anti-cancer activity through induction of apoptosis and inhibition of cancer cell proliferation. Additionally, tamarixetin has been shown to modulate various signaling pathways involved in cell survival and death.
|
|---|---|
| ln Vitro |
In vitro, tamarixetin exhibits potent antioxidant activity through free radical scavenging and metal chelation. It demonstrates anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines and modulating NF-κB signaling. The compound also shows anti-cancer activity by inducing apoptosis and inhibiting proliferation in various cancer cell lines. Its cardiovascular protective effects have been demonstrated in cellular models of oxidative stress.
|
| ln Vivo |
In vivo studies on tamarixetin are limited. Based on its mechanism of action, the compound may have potential in cardiovascular diseases, inflammatory disorders, and cancer. Its antioxidant and anti-inflammatory properties suggest potential in neurodegenerative diseases. Further in vivo studies are needed to fully characterize its pharmacological effects and therapeutic potential.
|
| Enzyme Assay |
For in vitro antioxidant assays, tamarixetin can be evaluated using DPPH, ABTS, or FRAP assays. The compound is incubated with radical solutions or ferric reducing agents, and the decrease in absorbance or increase in color is measured. Anti-inflammatory activity can be assessed by measuring inhibition of pro-inflammatory cytokine production in stimulated cells using ELISA.
|
| Cell Assay |
For in vitro cell-based assays, tamarixetin is typically tested on immune cells, cancer cell lines, or cardiovascular cells. Cells are treated with the compound at various concentrations (typically 1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. Cytokine production is measured by ELISA. Apoptosis is evaluated by flow cytometry. Signaling pathway modulation is assessed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for tamarixetin have not been extensively reported. Based on its anti-inflammatory, antioxidant, and anticancer activities, potential experimental models include inflammation models, cardiovascular disease models, and xenograft tumor models in mice. The compound could be administered orally or intraperitoneally, with relevant biomarkers assessed as pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Tamarind's known human metabolites include quercetin. Pharmacokinetic data for tamarixetin are limited. As a flavonoid, it is expected to have moderate oral bioavailability. The methoxy groups may enhance its metabolic stability compared to quercetin. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile. |
| Toxicity/Toxicokinetics |
Toxicological data for tamarixetin are limited. As a naturally occurring flavonoid, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Tamarindin is a monomethoxyflavonoid, a product of quercetin methylated at the O-4' position. It was isolated from Cyperus teneriffae. Tamarindin possesses metabolic and antioxidant properties. It is a 7-hydroxyflavonol, a monomethoxyflavonoid, and a tetrahydroxyflavonoid. Its functions are related to quercetin. Tamarindin has been reported to exist in Alhagi graecorum, Artemisia annua, and several other organisms with relevant data. See also: Red clover (Trifolium pratense) flower (partial).
Tamarixetin is a research-use only compound and has not been approved for clinical applications. It is a methylated derivative of quercetin found in Tamarix species. Its molecular weight and formula are well-characterized. It is available from various research chemical suppliers. Further research is needed to fully elucidate its pharmacological profile and therapeutic potential. |
| Molecular Formula |
C16H12O7
|
|---|---|
| Molecular Weight |
316.2623
|
| Exact Mass |
316.058
|
| CAS # |
603-61-2
|
| PubChem CID |
5281699
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
601.8±55.0 °C at 760 mmHg
|
| Melting Point |
265-268ºC
|
| Flash Point |
228.8±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.741
|
| LogP |
2.42
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
503
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FPLMIPQZHHQWHN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O7/c1-22-11-3-2-7(4-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3
|
| Chemical Name |
3,5,7-trihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~158.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1620 mL | 15.8098 mL | 31.6196 mL | |
| 5 mM | 0.6324 mL | 3.1620 mL | 6.3239 mL | |
| 10 mM | 0.3162 mL | 1.5810 mL | 3.1620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
